Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Visual impairment due to choroidal neovascularization (CNV) secondary to PM~* Best corrected visual acuity (BCVA) in the study eye \> 24 and \< 78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters~* High myopia (\> -6D), anterior-posterior elongation \> 26 mm; posterior changes compatible with the pathologic myopia~* Either lesion types in the study eye: subfoveal, juxtafoveal, extrafoveal~Exclusion Criteria:~* Patients with uncontrolled systemic or ocular diseases~* Blood pressure \> 150/90 mmHg~* History of pan-retinal, focal/grid laser photocoagulation or intraocular treatment with any anti-VEGF or vPDT in the study eye~* Intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab driven by disease activity (Type: EXPERIMENTAL): Participants received active ranibizumab on day 1. Thereafter they received ranibizumab treatment based on disease activity criteria
- Ranibizumab driven by stabilization criteria (Type: EXPERIMENTAL): Participants received ranibizumab on day 1 and month 1. Thereafter they received ranibizumab based on stabilization criteria for visual acuity
- Verteporfin PDT (Type: ACTIVE_COMPARATOR): Participants received active vPDT on day 1. From month 3 onwards participants could receive ranibizumab, vPDT or a combination of the two if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).